Skip to main content
padlock icon - secure page this page is secure

Open Access Compatibility Between Four Anti-TB Drugs and Tablet Excipients Determined By Microcalorimetry

Download Article:
 Download
(PDF 290.4 kb)
 
Previous isothermal microcalorimetry studies at 40 °C, with and without humidity (RH 75%), had shown no incompatibility between rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) and ethambutol HCl (EMB). The purpose of this study was to explore any interactions at an increased temperature of 50 °C and also to investigate the possibility of incompatibilities between the drugs and tablet excipients used in the most commonly prescribed commercial four-drug TB FDC. No incompatibilities were observed between the excipients, or when the excipients were tested with the four drugs individually. Incompatibility was observed with the four drugs combined.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Publication date: June 1, 2019

More about this publication?
  • Pharmazie is a leading journal in the field of pharmaceutical sciences. As a peer-reviewed scientific journal, Pharmazie is regularly indexed in the relevant databases like Web of science, Journal Citation Reports and many others. The journal is open for submissions from the whole spectrum of pharnaceutical sciences including Pharmaceutical Chemistry, Experimental and Clinical Pharmacology, Drug Analysis, Pharmaceutics, Pharmaceutical Biology, Clinical Pharmacy etc.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more